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ABSTRACT
Objective: Delineation variation of esophageal tumors remains a large source of geometric
uncertainty. In the present study, we investigated the inter- and intra-observer variation in esophageal
gross tumor volume (GTV) delineation and the impact of endoscopically implanted fiducial markers on
these variations.
Material/Methods: Ten esophageal cancer patients with at least two markers endoscopically
implanted at the cranial and caudal tumor borders and visible on the planning computed tomography
(pCT) were included in this study. Five dedicated gastrointestinal radiation oncologists independently
delineated GTVs on the pCT without markers and with markers. The GTV was first delineated on pCTs
where markers were digitally removed and next on the original pCT with markers. Both delineation
series were executed twice to determine intra-observer variation. For both the inter- and intra-observer
analyses, the generalized conformity index (CIgen), and the standard deviation (SD) of the distances
between delineated surfaces (i.e., overall, longitudinal, and radial SDs) were calculated. Linear mixed-
effect models were used to compare the without and with markers series (a¼ 0.05).
Results: Both the inter- and intra-observer CIgen were significantly larger in the series with markers than
in the series without markers (p< .001). For the series without markers vs. with markers, the inter-obser-
ver overall SD, longitudinal SD, and radial SD was 0.63 cm vs. 0.22 cm, 1.44 cm vs. 0.42 cm, and 0.26 cm
vs. 0.18 cm, respectively (p< .05); moreover, the intra-observer overall SD, longitudinal SD, and radial SD
was 0.45 cm vs. 0.26 cm, 1.10 cm vs. 0.41 cm, and 0.22 cm vs. 0.15 cm, respectively (p< .05).
Conclusion: The presence of markers at the cranial and caudal tumor borders significantly reduced
both inter- and intra-observer GTV delineation variation, especially in the longitudinal direction. Our
results endorse the use of markers in GTV delineation for esophageal cancer patients.
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Introduction
Chemoradiotherapy plays a vital role in the curative treat-
ment of esophageal cancer [1]. The primary objective of
esophageal cancer radiotherapy (RT) is to deliver a high radi-
ation dose to the target volume while minimizing the dose
delivered to the organs at risk (OARs). Target volume defin-
ition remains one of the largest sources of geometric uncer-
tainty. For esophageal cancer it can be notoriously
challenging to visualize the true tumor extent on an RT plan-
ning computed tomography (pCT) scan, particularly in longi-
tudinal direction, which hampers an accurate delineation of
the gross tumor volume (GTV). Ideally, delineation variation
is determined on clinical target volume (CTV) delineations.
However, the esophageal CTV can also be determined by
elective lymph nodes, this is thus more a matter of clinical
judgment than delineation variation. Since the cranial and
caudal border of the CTV, which is – according to common
practice – directly extrapolated from the delineated GTV in
longitudinal direction, an accurate GTV in the longitudinal
direction is crucial for CTV extent determination. The geo-
metric uncertainty in delineation can lead to an underestima-
tion or overestimation of the tumor extent and hence to the
risk of inadequate tumor treatment or increased radiation
damage to OARs. Moreover, with future studies focusing at
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dose escalation of the GTV, a precise GTV delineation will
become even more vital.
18F-fluoro-2-deoxy-d-glucose (FDG) positron emission tom-
ography (PET) provides additional information on metabolic
activity (i.e., glucose utilization) of the tumor. Addition of this
FDG-PET information to a diagnostic CT is found to be useful
for diagnosis and staging of esophageal cancer [2]. FDG-PET
has shown limited specificity visualizing esophageal tumor
extent, since it cannot differentiate tumor from inflammation.
Moreover, the nonstandardized way of incorporating FDG-
PET/CT information in the tumor delineation process, results
in FDG-PET/CT having limited value in GTV delineation [3,4].
Furthermore, a recent study trying to decrease the variation
in esophageal target volume delineation by adding PET/CT
information was not able to show a significant reduction [5].
Therefore, the use of FDG-PET/CT in target volume delinea-
tion remains subject of debate and still requires further clin-
ical validation.
Endoscopic ultrasound (EUS) examination is still considered
the most reliable tool for assessment of macroscopic tumor
extension and correlates significantly with pathological tumor
extension [6,7]. The use of endoscopy/EUS-guided implanted
markers at the cranial and caudal borders of the macroscopi-
cal tumor enables projection of the (echo)endoscopic tumor
extent onto the pCT [8–10], with no macroscopic spread
found beyond (echo)endoscopically determined tumor borders
[11]. We hypothesized that this addition of information to the
otherwise poorly discriminative pCT images may reduce the
observer variation in target volume delineation.
The aim of this study was to quantify the inter- and intra-
observer variation of esophageal GTV delineation. Further,
we investigated whether the use of markers placed on endo-
scopically determined cranial and caudal tumor borders can
significantly reduce the inter- and intra-observer delineation
variation in esophageal cancer patients.
Material and methods
Patients and observers
Data of 10 patients with curable esophageal cancer (cT1-4a,
N0-1, M0) treated with RT, were retrospectively selected and
anonymized (Table 1). All patients were selected from an ear-
lier pilot study population concerning feasibility of marker
placement [8]. Each patient had at least two markers
implanted (i.e., one at the cranial tumor border and one at
the caudal tumor border) by a dedicated gastroenterologist,
clearly visible on the pCT, as is clinical practice at our center.
This procedure was reported in detail in an earlier study [8].
The goal was to place the markers exactly on the cranial and
caudal tumor borders; however, this was not always feasible
(e.g., due to stenosis). Because the marker position was
aimed to indicate true tumor extent, the distance between
the placed marker and the (echo)endoscopic tumor border
was measured by fluoroscopy; the tumor border was indi-
cated by the tip of the (echo)endoscopy after marker
implantation in the fluoroscopy. This distance between the
marker and the tumor border was reported in the medical
file available during delineation. Three types of markers were
implanted: a solid gold marker (5mm long with diameter of
0.43–0.64mm; Cook Medical, Limerick, Ireland), a flexible coil-
shaped gold marker (5–10mm long with diameter of
0.35mm; Visicoil, Core Oncology, Santa Barbara, CA, USA), or
an injectable radiopaque hydrogel marker (0.4mL; TraceIT
Tissue Marker; Augmenix Inc, Waltham, MA, USA).
In the data selection process, tumor locations (proximal,
mid-thoracic, distal) and preexistent primary tumor visibility
on the pCT as determined by an experienced radiologist (i.e.,
poorly visible or clearly visible) were taken into account, pur-
suing a heterogeneous mix of esophageal tumor characteris-
tics (Table 1). Tumor location was classified according to the
American Joint Committee on Cancer [12]. Tumor visibility
on pCT was qualitatively rated (5-point ordinal scale) by an
experienced gastrointestinal radiologist, whereas tumors with
a score of 1–2 were considered poorly visible, and tumors
with a score 3–5 as clearly visible. The visibility score was
unknown to the observers. A total of five experienced radi-
ation oncologists with 4–28 years of experience in gastro-
intestinal oncology (i.e., observers) participated in this study.
CT dataset
For each patient, a 3D pCT scan (120 kV, mA depending per
patient (SmartA; General Electric Company, Waukesha, WI,
USA) (mean 180mA), axial slice thickness 2.5 or 3.0mm, in-
plane pixel size 1.0 1.0mm) ranging from the bottom edge
of the mandible to the lower border of the kidneys was
available.To be able to delineate on both pCTs with and
Table 1. Patient, tumor, and fiducial marker characteristics.
Patient Age Sex
Tumor
length
(cm) TNM Histology
Tumor
location
Tumor
visibility
on pCT
Cardia
involvement
Marker
type Markers on tumor border?
No. of
markers
on pCT
1 73 M 4 T2N0M0 SCC Proximal Clear No HG Yes 3
2 71 M 5 T4aN2M0 SCC Distal Clear Yes HG Yes 5
3 84 M 7 T3N1M0 AD Distal Clear No HG Yes 3
4 70 M 5 T2N1M0 SCC Proximal Poor No FM 1 cm below caudal border 3
5 65 F 5 T2N0M0 SCC Middle Poor No FM 0.5 cm below cranial border 3
6 45 M 4 T2N1M0 AD Distal Poor Yes FM Yes 3
7 61 M 6 T3N2M0 AD Distal Poor Yes FM Yes 3
8 63 M 10 T3N2M0 AD Distal Clear Yes FM 2 cm below caudal border 4
9 75 M 3 T3N1M0 SCC Distal Poor No SM Yes 2
10 61 M 6 T3N1M0 AD Distal Clear No FM 1 cm above caudal border 3
Abbreviations: AD: adenocarcinoma; F: female; FM: flexible coil-shaped gold marker; HG: injectable radiopaque hydrogel; M: male; pCT: planning computed tom-
ography; SCC: squamous cell carcinoma; SM: solid rigid gold marker.
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without markers in the same patient, we digitally removed
the markers from the originally acquired pCTs using in-house
developed software. The graphical user interface of the soft-
ware was designed to follow several steps. First, on the pCT
with markers, for each marker a region of interest (ROI) com-
pletely encompassing the marker was manually created.
Next, a second ROI that contained the esophageal wall in
the vicinity of the marker was created. Third, the CT values
in the first ROI were replaced with values based on the CT
values in the second ROI while ensuring as best as possible
the use of representative similar patterns and presence of
noise [13], resulting in the creation of a pCT without markers.
Figure 1 gives an illustration of a single pCT, with and with-
out markers.
Delineation protocol and study design
The GTV was defined as the macroscopically visible tumor, pos-
sible involved lymph nodes were not included. Based on all
diagnostic information available (EUS/endoscopy reports and
diagnostic CT), the observers delineated the GTVs on the axial
slices of the pCT using Big Brother target volume delineation
software [14] using a strict delineation protocol (Supplementary
Appendix). Sagittal and coronal views of the pCT scan were
shown to the observer simultaneously. Observers were free to
adjust window level/width at their own discretion.
The study consists of four delineation series: two series
without markers and two with markers (Supplementary
Figure A1). In the series without markers, the observers were
Figure 1. Delineations of patient 5 on the planning computed tomography without (left) and with markers (right). The delineations of the individual observers are
indicated in different colors. The colors match the same observer throughout this work. Red arrows indicate fiducial markers. Insert demonstrates transversal slice
without delineations.
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asked to delineate the GTV on the pCT at two time points
with a time interval of at least 3 weeks between the first and
second time points. At least 6 weeks after completion of the
series without markers, the observers were asked to delin-
eate the GTV on the pCT with markers, twice again, under
the same conditions. During this delineation series, both the
fiducial markers and the information from the pCT scan were
taken into account when delineating the GTV.
Inter-observer variation
Per patient, the average volume of the five GTVs and the
generalized conformity index (CIgen) [15] of the five GTVs
were calculated using Big Brother software (Supplementary
Figure A1). CIgen is defined as the ratio of the sum of the
overlapping volumes between all observer pairs and the sum
of the encompassing volumes between the same observer
pairs, where CIgen = 0 means no overlap and CIgen = 1 means
full overlap.
For each patient per series, the median GTV of the five
GTVs was reconstructed using Big Brother software. This
median GTV comprises the voxels delineated by at least 50%
(i.e., 3 out of 5) of the observers. The surface of the median
GTV (i.e., median surface) was sampled into a 3D mesh with
approximately equidistant (0.5mm) vertices. In the direction
perpendicular to the median surface, the 3D distance from
each vertex on the median surface to the five surfaces of the
delineated GTVs was measured. Per vertex, the standard
deviation (SD) of these five distances (i.e., local SD) was used
as a measure of local inter-observer variation. Per patient,
the inter-observer overall SD was defined as the root mean
square (RMS) of all local SDs [14].
In addition to the abovementioned inter-observer overall
SD, we calculated the inter-observer overall SD in the longi-
tudinal (i.e., CC) and radial (i.e., in the axial plane) direction
separately. The longitudinal SD was defined as the RMS of
local SDs associated with vertices sampled in the CC direc-
tion, for the most cranial and caudal slice (i.e., end) of each
delineation. The radial SD was defined as the RMS of local
SDs associated with vertices sampled in the axial plane,
including only the axial slices of the pCT that contained
delineations from all observers.
Intra-observer variation
For each patient in the two series without markers, the aver-
age volume of the two GTVs and the CIgen of the two GTVs
delineated by the same observer were calculated
(Supplementary Figure A1). Moreover, for each observer and
each patient, based on the two GTVs, the local and overall
SDs were calculated. In addition, the longitudinal and radial
SDs were calculated. These measures were also calculated for
the two series with markers.
Statistical comparison
To investigate whether with the use of markers a signifi-
cantly different inter-/intra-observer variation is associated,
linear mixed-effects models were applied to compare the ser-
ies without markers to the series with markers. The series
were compared in terms of inter-/intra-observer variation
measures, including the average volume of GTVs, CIgen, and
overall SDs as well as the longitudinal and radial SDs. In
these models, the marker presence (i.e., without or with
markers) was taken as a fixed effect; the patient associated
with delineation time point (i.e., the first or the second time)
or observer, tumor visibility (i.e., clearly or poorly visible), and
cardiac involvement were taken as random effects. The same
fixed effects were identified when stratifying the patient
group (i.e., in the patient group with clearly and poorly vis-
ible tumors separately). All statistical comparison was done
using the R software (version 3.3.2 [2016]; R Foundation for
Statistical Computing, Vienna, Austria) with significance level
a¼ 0.05 [16,17].
Results
Each observer made four delineations per patient, yielding a
total of 200 GTV delineations. Observer 1 accidentally used
incorrect diagnostic information when delineating patient 2
(Supplementary Figure A2), the delineations of this observer
for patient 2 were therefore excluded. The average time
interval between all delineation series was 11 weeks (range:
3–20 weeks).
Inter-observer variation
For the two series without markers versus the two with
markers, the mean (range) of average volumes of the five
delineated GTVs was 33.81 (10.72–89.86) cm3 vs. 35.92
(8.26–91.86) cm3 and the mean (range) of CIgen was 0.54
(0.29–0.80) vs. 0.68 (0.42–0.83). A significant difference was
found in the CIgen (p< .001) for patients with poorly visible
tumors on the CT scan but not for patients with clearly vis-
ible tumors. Complete results are listed in supplementary
Table A1.
The pattern of local SD is very heterogeneous between
patients upon visual inspection, as shown in Figure 2. It is
clear that the largest differences exist in the cranial and cau-
dal regions. In the series with markers, the local SD was
decreased particularly in the regions where in the series
without markers a large (>1 cm) local SD was found.
However, for patient 8, an increased local SD in the caudal
part was found. For patient 2, a small variation remained at
the curvatura minora region but was reduced compared to
the delineations on pCT without markers.
Table 2 summarizes the overall, longitudinal, and radial
SDs. For all 10 patients, a significant reduction (p< .001) of
the overall SD, from 0.63 cm to 0.22 cm, was seen in the ser-
ies with markers compared to the series without markers
(Table 2). The reduction was more pronounced in the poorly
visible tumors compared to the clearly visible tumors.
Compared to the series without markers, the longitudinal SD
at both the cranial and caudal end was significantly reduced
by 1.02 cm on average for all patients (p< .001). The radial
SD was 0.26 cm in the series without markers versus 0.18 cm
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with markers. The largest reduction in radial SD was seen at
the curvatura minora in patient 2, who had a gastroesopha-
geal junction tumor (Figure 2).
The delineation time point showed no variance (<0.1 cm)
in these linear mixed-effects models. This implies that there
was no learning curve between the original and repeated
delineations (Table 2 and Supplementary Table A1).
Moreover, the cardiac involvement was found to have no
statistically significant effect on in the inter-observer vari-
ation measures.
Intra-observer variation
For the series without markers versus with markers, the
mean (range) of the average volume of the two GTVs
delineated by each observer was 19.81 (6.35–88.14) cm3 vs.
18.48 (6.13–87.95) cm3 and the mean (range) of the CIgen of
the two GTVs was 0.68 (0.33–0.86) vs. 0.75 (0.60–0.84). For
both groups of patients with clearly and poorly visible
markers, the CIgen was significantly increased in the series
with markers compared to that without markers (p< .05)
(Supplementary Table A2).
Table 3 lists the findings concerning the intra-observer
overall SDs as well as the longitudinal and radial SDs. For all
patients, a significant reduction of the overall SD by 0.19 cm
on average was noticed, when comparing the series with
markers to those without markers (p< .01) (Table 3). The
same held for patients with poorly visible tumors (p< .05)
but not for patients with clearly visible tumors (p¼ .06).
Comparison of the series with markers to those without
markers indicated that the intra-observer longitudinal SD at
both cranial and caudal ends was significantly reduced by
0.69 cm on average for all patients (p< .001). The intra-obser-
ver radial SD was 0.22 cm in the series without markers ver-
sus 0.15 cm in the series with markers (p< .01). Further, the
cardiac involvement had no statistically significant effect on
the intra-observer variation measures.
Discussion
To the best of our knowledge, this is the first study to quan-
tify GTV delineation variation in esophageal cancer RT with
fiducial markers. Our findings show that delineation variation
is a major geometric uncertainty for esophageal cancer RT,
especially in the longitudinal direction. This might lead to a
clinically relevant systematic error in the treatment planning
and delivery process. Marker implantation at craniocaudal
tumor borders resulted in a significant reduction in both
inter- and intra-observer variation, also suggesting reduced
geometric uncertainty.
Target volume delineation variation is a difficult entity to
grasp. Throughout literature, different kinds of parameters
Figure 2. Anterior view of the local surface distance variation (SD) over the five observers projected on the median surface of the 10 patients in the series without
and with markers. Column (a) the original series (b) the repeated series.
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have been used to quantify and compare delineation vari-
ation, ranging from describing the distribution of volumes
(e.g., Vmax/Vmin), to concordance measurements (e.g., Jaccard
conformity index). These parameters provide different infor-
mation about the delineation variation, subsequently, they
cannot directly be compared [18]. For esophageal cancer,
limited studies reported on delineation variation. In a large
pretrial quality assurance study of the SCOPE 1 trial, a large
inter-observer variation was seen with a median Jaccard con-
formity index for GTV of 0.69 [19]. An older series performed
at the start of the 3D planning era, also demonstrated a
large uncertainty with a Vmax/Vmin ratio up to 6 [20]. A disad-
vantage of these parameters is that they all compare relative
volumes instead of absolute distances and thus cannot be
directly compared or translated into margins. This difficulty
can be overcome by quantifying absolute distances and
assessing both positional and volume change in a single
measurement by means of the median surface distance [21].
Large inter- and intra-observer overall SDs of 0.63 cm and
0.45 cm were seen in the absence of markers. Observer varia-
tions were predominantly determined in the longitudinal dir-
ection (inter-observer: 1.44 cm; intra-observer: 1.10 cm), which
is obvious since GTV borders in the radial direction are more
clearly visible on the pCT due to the proximity of contrasting
adjacent structures (i.e., lungs, vertebrae, heart).
Addition of markers in the pCT decreased the delineation
variation particularly in the longitudinal direction in both
inter- and intra-observer longitudinal SDs. With largest reduc-
tions seen in patients with poorly visible tumors on pCT, sug-
gesting that the use of markers might have had more
impact in this group. Nevertheless, when the tumor flattens
to mucosal level at the CC borders, it remains challenging to
determine the true tumor extent, regardless of the bulkiness
of the central part.
Only in one patient (patient 8), we found no reduction in
inter-observer longitudinal SD by the use of markers. In this
patient who also had cardiac involvement, the marker was
placed 2 cm below the caudal (echo)endoscopic tumor bor-
der, yet again inducing ambiguity on true tumor extent.
Nonetheless, in the other three patients receiving a marker
at some distance from the (echo)endoscopic tumor border,
no increase in longitudinal SD was seen. This might be
explained by the fact that their markers were not placed fur-
ther than 1cm from the (echo)endoscopic tumor border and
no cardiac involvement was present, emphasizing the
importance of marker placement on or very nearby
tumor borders.
Looking at radial SD no difference with presence of
markers is suspected, since markers only provide information
on the tumor extent in longitudinal direction. Only for
patient 2, a small reduction was seen in the radial SD
between observers, possibly because markers placed in the
cardia also provided information on the radial direction of
the tumor extent. A significant radial SD reduction was also
observed for the intra-observer variation in the series with
markers compared to the series without markers. The pres-
ence of markers might have led to more confident observers,
demonstrated by a significant reduction in also intra-obser-
ver overall and longitudinal SDs.
There are two different sources for target delineation vari-
ation. Foremost, different observers have different clinical
judgment on what to encompass. These differences can be
reduced by strict treatment protocols and delineation guide-
lines. Therefore, we instigated a strict delineation protocol in
this study. Nonetheless, in patient 6, one observer consist-
ently delineated a target volume extending below the delin-
eations of the other four observers, in both series without
markers, but not in the series with markers, suggesting a dif-
ference in clinical judgment (Supplementary Figure A3). If we
exclude the delineations of this observer for this patient, the
inter-observer overall SD would be 0.55 cm instead of 0.
63 cm for all patients. Since target delineation remains prone
to human errors, markers can also assist in preventing this
type of geographic errors. The small difference between
intra-observer and inter-observer variation is remarkable; that
is, most contouring differences cannot be attributed to inter-
pretation differences but are mainly due to the poor visibility
of the border, adding an element of randomness to the
delineation process without markers.
Secondly, even with the same treatment protocol and
delineation guidelines, delineation is still subject to inter-
and intra-observer variation. Safety margins are added to
compensate for delineation variations. Since the intra-obser-
ver variation is inherently incorporated in the inter-observer
variation, when calculating the PTV margin only the latter
should be taken into account. Because the longitudinal CTV
extent is directly extrapolated from the longitudinal GTV, in
absence of pathological lymph nodes, an improvement in
longitudinal GTV variation will consequently lead to an
improvement in longitudinal CTV delineation variation, and
thus in a reduction in PTV, because a longitudinal SD of
0.42 cm instead of 1.44 cm would be used for delineation
variation in the commonly used margin recipe [22]. Other
uncertainties encompassed by the PTV – as quantified in ear-
lier studies – were many times smaller than the longitudinal
delineation variation without markers [23,24].
In addition to implantation of markers, using magnetic
resonance imaging (MRI) might reduce delineation variation,
as has been proven for other treatment sites [25–27]. For
esophageal cancer, this is an ongoing research field. There is
a promising study showing an excellent correlation between
histopathological findings and findings on diffusion weighted
imaging scans regarding the esophageal squamous cell car-
cinoma GTV length [28]. In the absence of an MRI-only work-
flow in treatment delivery, it remains necessary to register
the MRI scan with the pCT and markers are still helpful for
positional verification with CBCT, potentially, markers that
are also visible on MRI, seem optimal [29]. Problems could
occur when large anatomical differences exist between both
scans, which is imaginably because of its intrinsic mobility
subject to gastric filling and respiratory and cardiac motion.
However, when an MRI-only workflow is established, with
the superior soft-tissue contrast in MRI, we predict a large
potential benefit in esophageal cancer target volume
delineation.
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In conclusion, large inter- and intra-observer variation is
seen in esophageal GTV delineation, especially in the longitu-
dinal direction. The presence of markers at tumor borders
can significantly reduce both inter- and intra-observer delin-
eation variation in all directions. Since markers mainly assist
with the determination of the cranial and caudal tumor bor-
ders, the largest reduction was seen in the longitudinal direc-
tion. Our results endorse the use of markers in esophageal
GTV delineation to reduce the geometric uncertainty and
hence a higher treatment accuracy.
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